Cited 0 time in
Preemptive Living-Donor Renal Transplantation: Outcome and Clinical Advantages
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yoo, Sang-Woo | - |
| dc.contributor.author | Kwon, Oh Jung | - |
| dc.contributor.author | Kang, Chong-myung | - |
| dc.date.accessioned | 2022-12-20T23:45:36Z | - |
| dc.date.available | 2022-12-20T23:45:36Z | - |
| dc.date.issued | 2009-01 | - |
| dc.identifier.issn | 0041-1345 | - |
| dc.identifier.issn | 1873-2623 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/177376 | - |
| dc.description.abstract | Introduction. Kidney transplant recipients have a higher quality of life and consume fewer health care resources compared with patients on dialysis. However, optimal timing of transplantation has been controversial. Recent studies have clearly demonstrated that preemptive renal transplantation is associated with better graft survival, lower complications, and better cost-effective outcomes. We evaluated differential effects on long-term outcomes according to dialysis type/duration versus no dialysis. Materials and Methods. We retrospectively analyzed 499 cases of first living-donor kidney transplantations performed in our center from January 1990 to January 2007. We compared 3 groups according to graft survival, acute and chronic rejection, postoperative complication, and delayed graft function rates. The mean duration of follow-up was 119.1 +/- 47.2 months. Results. Among 499 cases, 81 cases were preemptive renal transplantations with 418 cases hemodialysis [HD], 343 cases, peritoneal dialysis [PD] 75 cases) performed after dialysis. The 1-, 5-, and 10-year graft survival rates were 98.8%, 89.5%, 79.4% among the preemptive renal transplantation group and 92.4%, 78.2%, and 69.2% and 85.3%, 74.5%, and 68.2% (P =.03) in the dialysis groups (HD, PD), respectively. The differential effect of pretransplantation IID or PD was not significant. However, the graft survival rates in the HD group were not significantly higher than the PD group (P = .61). The duration of dialysis was not associated with graft survival. Conclusion. We suggest that preemptive renal transplantation should be the first choice of treatment for patients with end-stage renal disease. | - |
| dc.format.extent | 4 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Appleton & Lange | - |
| dc.title | Preemptive Living-Donor Renal Transplantation: Outcome and Clinical Advantages | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.transproceed.2008.09.063 | - |
| dc.identifier.scopusid | 2-s2.0-60649084782 | - |
| dc.identifier.wosid | 000263749100032 | - |
| dc.identifier.bibliographicCitation | Transplantation Proceedings, v.41, no.1, pp 117 - 120 | - |
| dc.citation.title | Transplantation Proceedings | - |
| dc.citation.volume | 41 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 117 | - |
| dc.citation.endPage | 120 | - |
| dc.type.docType | Article; Proceedings Paper | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Immunology | - |
| dc.relation.journalResearchArea | Surgery | - |
| dc.relation.journalResearchArea | Transplantation | - |
| dc.relation.journalWebOfScienceCategory | Immunology | - |
| dc.relation.journalWebOfScienceCategory | Surgery | - |
| dc.relation.journalWebOfScienceCategory | Transplantation | - |
| dc.subject.keywordPlus | DIALYSIS | - |
| dc.subject.keywordPlus | ACTIVATION | - |
| dc.subject.keywordPlus | RECOVERY | - |
| dc.subject.keywordPlus | FAILURE | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0041134508015741?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
